Vitamin D and nonalcoholic fatty liver disease (NAFLD): Is it more than just an association?

Vitamin D is a secosteroid with known effects on calcium homeostasis that has recently been shown to have other significant functions regarding immune modulation, cell differentiation and proliferation, and the inflammatory response. As our understanding of the many functions of vitamin D has grown, the presence of vitamin D deficiency (VDD) has become more evident in Western populations. Concomitantly, nonalcoholic fatty liver disease (NAFLD) has become the most common cause of chronic liver disease. NAFLD and VDD are often found together, and while this is not unexpected, given their similar associations with obesity and sedentary lifestyle, a growing body of evidence points to a closely linked and potentially causative relationship between VDD and NAFLD. The epidemiologic association between VDD and NAFLD as well as the role of VDD in the pathogenesis of NAFLD and the available evidence on the clinical utility of vitamin D replacement in NAFLD populations are discussed. (Hepatology 2013;53:1166–1174)

[1]  Fei Li,et al.  FXR signaling in the enterohepatic system , 2013, Molecular and Cellular Endocrinology.

[2]  D. Torres,et al.  Features, diagnosis, and treatment of nonalcoholic fatty liver disease. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[3]  James E. Nelson,et al.  Vitamin D deficiency in obese rats exacerbates nonalcoholic fatty liver disease and increases hepatic resistin and toll‐like receptor activation , 2012, Hepatology.

[4]  A. Vaidya,et al.  The Independent Association Between 25‐Hydroxyvitamin D and Adiponectin and Its Relation With BMI in Two Large Cohorts: The NHS and the HPFS , 2012, Obesity.

[5]  J. Stockman,et al.  Metabolic Syndrome and Altered Gut Microbiota in Mice Lacking Toll-Like Receptor 5 , 2012 .

[6]  Leilani St Anna,et al.  Clinical inquiries. Which regimen treats vitamin D deficiency most effectively? , 2011, The Journal of family practice.

[7]  S. Reif,et al.  Vitamin D inhibits proliferation and profibrotic marker expression in hepatic stellate cells and decreases thioacetamide-induced liver fibrosis in rats , 2011, Gut.

[8]  A. Kahraman,et al.  Vitamin D ameliorates stress ligand expression elicited by free fatty acids in the hepatic stellate cell line LX-2. , 2011, The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology.

[9]  Chao-Long Chen,et al.  Impact of artificial sunlight therapy on the progress of non-alcoholic fatty liver disease in rats. , 2011, Journal of hepatology.

[10]  S. Morini,et al.  Strong association between non alcoholic fatty liver disease (NAFLD) and low 25(OH) vitamin D levels in an adult population with normal serum liver enzymes , 2011, BMC medicine.

[11]  J. Mitri,et al.  Vitamin D and type 2 diabetes: a systematic review , 2011, European Journal of Clinical Nutrition.

[12]  Jonathan C. Cohen,et al.  Human Fatty Liver Disease: Old Questions and New Insights , 2011, Science.

[13]  S. Bischoff,et al.  Role of tumor necrosis factor α (TNFα) in the onset of fructose-induced nonalcoholic fatty liver disease in mice. , 2011, The Journal of nutritional biochemistry.

[14]  V. de Lédinghen,et al.  A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. , 2011, Journal of hepatology.

[15]  N. Chalasani,et al.  Serum Vitamin D Concentrations and Unexplained Elevation in ALT Among US Adults , 2011, Digestive Diseases and Sciences.

[16]  C. Housset,et al.  Vitamin D and the vitamin D receptor in liver pathophysiology. , 2011, Clinics and research in hepatology and gastroenterology.

[17]  G. Chrousos,et al.  Hypovitaminosis D associations with adverse metabolic parameters are accentuated in patients with Type 2 diabetes mellitus: A body mass index-independent role of adiponectin? , 2011, Journal of Endocrinological Investigation.

[18]  B. Clarke,et al.  Vitamin D insufficiency. , 2011, Mayo Clinic proceedings.

[19]  D. Brenner,et al.  Role of Toll-Like Receptors and Their Downstream Molecules in the Development of Nonalcoholic Fatty Liver Disease , 2011, Gastroenterology research and practice.

[20]  H. Tilg,et al.  Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis , 2010, Hepatology.

[21]  J. Hardies,et al.  Pioglitazone in the treatment of NASH: the role of adiponectin , 2010, Alimentary pharmacology & therapeutics.

[22]  R. Recker,et al.  Comprehensive association analysis of nine candidate genes with serum 25-hydroxy vitamin D levels among healthy Caucasian subjects , 2010, Human Genetics.

[23]  H. Tilg,et al.  Anti-inflammatory effects of excessive weight loss: potent suppression of adipose interleukin 6 and tumour necrosis factor α expression , 2010, Gut.

[24]  P. Menheere,et al.  Regulatory T cell function correlates with serum 25-hydroxyvitamin D, but not with 1,25-dihydroxyvitamin D, parathyroid hormone and calcium levels in patients with relapsing remitting multiple sclerosis , 2010, The Journal of Steroid Biochemistry and Molecular Biology.

[25]  C. Geisler,et al.  Vitamin D controls T cell antigen receptor signaling and activation of human T cells , 2010, Nature Immunology.

[26]  K. Flegal,et al.  Prevalence and trends in obesity among US adults, 1999-2008. , 2010, JAMA.

[27]  Jian Zhang,et al.  Resistin Up-Regulates COX-2 Expression via TAK1-IKK-NF-κB Signaling Pathway , 2010, Inflammation.

[28]  K. Cusi Role of insulin resistance and lipotoxicity in non-alcoholic steatohepatitis. , 2009, Clinics in liver disease.

[29]  G. Groothuis,et al.  1α,25‐dihydroxyvitamin D3 triggered vitamin D receptor and farnesoid X receptor‐like effects in rat intestine and liver in vivo , 2009, Biopharmaceutics & drug disposition.

[30]  Xiping Xu,et al.  Heritability and environmental factors affecting vitamin D status in rural Chinese adolescent twins. , 2009, The Journal of clinical endocrinology and metabolism.

[31]  S. Chanprasertyothin,et al.  The association between vitamin D status and circulating adiponectin independent of adiposity in subjects with abnormal glucose tolerance , 2009, Endocrine.

[32]  E. Tsochatzis,et al.  Adipokines in Nonalcoholic Steatohepatitis: From Pathogenesis to Implications in Diagnosis and Therapy , 2009, Mediators of inflammation.

[33]  S. Khalifé,et al.  Vitamin D in relation to metabolic risk factors, insulin sensitivity and adiponectin in a young Middle-Eastern population. , 2009, European journal of endocrinology.

[34]  P. Scherer,et al.  Adiponectin in health and disease: evaluation of adiponectin-targeted drug development strategies. , 2009, Trends in pharmacological sciences.

[35]  D. Bikle Nonclassic actions of vitamin D. , 2009, The Journal of clinical endocrinology and metabolism.

[36]  D. van der Poorten,et al.  Disease-specific mechanisms of fibrosis: hepatitis C virus and nonalcoholic steatohepatitis. , 2008, Clinics in liver disease.

[37]  J. Ruidavets,et al.  Energy intake is associated with endotoxemia in apparently healthy men. , 2008, The American journal of clinical nutrition.

[38]  K. Badenhoop,et al.  CYP2R1 (vitamin D 25‐hydroxylase) gene is associated with susceptibility to type 1 diabetes and vitamin D levels in Germans , 2007, Diabetes/metabolism research and reviews.

[39]  G. Shulman,et al.  Obesity-associated improvements in metabolic profile through expansion of adipose tissue. , 2007, The Journal of clinical investigation.

[40]  G. Targher,et al.  Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. , 2007, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[41]  P. Lipsky,et al.  Modulatory Effects of 1,25-Dihydroxyvitamin D3 on Human B Cell Differentiation , 2007, The Journal of Immunology.

[42]  J. Carvalheira,et al.  Loss-of-Function Mutation in Toll-Like Receptor 4 Prevents Diet-Induced Obesity and Insulin Resistance , 2007, Diabetes.

[43]  J. Ferrières,et al.  Metabolic Endotoxemia Initiates Obesity and Insulin Resistance , 2007, Diabetes.

[44]  R. Recker,et al.  Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. , 2007, The American journal of clinical nutrition.

[45]  M. Wjst,et al.  A genome-wide linkage scan for 25-OH-D3 and 1,25-(OH)2-D3 serum levels in asthma families , 2007, The Journal of Steroid Biochemistry and Molecular Biology.

[46]  J. Flier,et al.  TLR4 links innate immunity and fatty acid-induced insulin resistance. , 2006, The Journal of clinical investigation.

[47]  H. Tilg,et al.  Nonalcoholic fatty liver disease: Cytokine-adipokine interplay and regulation of insulin resistance. , 2006, Gastroenterology.

[48]  J. Adams,et al.  Toll-Like Receptor Triggering of a Vitamin D-Mediated Human Antimicrobial Response , 2006, Science.

[49]  I. Macintyre,et al.  The regulation of vitamin D metabolism , 1975, Calcified Tissue Research.

[50]  C. Mathieu,et al.  Immunoregulation by 1,25-dihydroxyvitamin D3: Basic concepts , 2005, The Journal of Steroid Biochemistry and Molecular Biology.

[51]  S. Sanderson,et al.  The natural history of nonalcoholic fatty liver disease: a population-based cohort study. , 2005, Gastroenterology.

[52]  G. Fantuzzi Adipose tissue, adipokines, and inflammation. , 2005, The Journal of allergy and clinical immunology.

[53]  M. Hewison,et al.  Expression of 25-hydroxyvitamin D3-1α-hydroxylase in pancreatic islets , 2004, The Journal of Steroid Biochemistry and Molecular Biology.

[54]  M. Hewison,et al.  Expression of 25-hydroxyvitamin D3-1alpha-hydroxylase in pancreatic islets. , 2004, The Journal of steroid biochemistry and molecular biology.

[55]  Y. Takeuchi,et al.  Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. , 2004, The Journal of clinical investigation.

[56]  I. Campbell,et al.  The plasma insulin and growth hormone response to oral glucose: Diurnal and seasonal observations in the antarctic , 1975, Diabetologia.

[57]  J. Dancey,et al.  A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma , 2003, British Journal of Cancer.

[58]  H. Degreef,et al.  1,25‐dihydroxyvitamin D3 inhibits ultraviolet B‐induced apoptosis, Jun kinase activation, and interleukin‐6 production in primary human keratinocytes , 2003, Journal of cellular biochemistry.

[59]  Yu Wang,et al.  The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. , 2003, The Journal of clinical investigation.

[60]  Arya M. Sharma,et al.  The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome? , 2003, The international journal of biochemistry & cell biology.

[61]  T. Zimmers,et al.  Suppressor of Cytokine Signaling-3 (SOCS-3), a Potential Mediator of Interleukin-6-dependent Insulin Resistance in Hepatocytes* , 2003, The Journal of Biological Chemistry.

[62]  E. Wolf,et al.  Impaired insulin secretory capacity in mice lacking a functional vitamin D receptor , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[63]  A. Moser,et al.  Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease , 2003, Hepatology.

[64]  N. Dávila,et al.  Identification of a Vitamin D response element in the human insulin receptor gene promoter , 2003, The Journal of Steroid Biochemistry and Molecular Biology.

[65]  N. Dávila,et al.  Transcriptional activation of the human insulin receptor gene by 1,25‐dihydroxyvitamin D3 , 2002, Cell biochemistry and function.

[66]  Shu Q. Liu,et al.  1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system , 2002 .

[67]  Shu Q. Liu,et al.  1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. , 2002, The Journal of clinical investigation.

[68]  Huub F. J. Savelkoul,et al.  1α,25-Dihydroxyvitamin D3 Has a Direct Effect on Naive CD4+ T Cells to Enhance the Development of Th2 Cells1 , 2001, The Journal of Immunology.

[69]  I. Shimomura,et al.  Leptin, troglitazone, and the expression of sterol regulatory element binding proteins in liver and pancreatic islets. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[70]  C. Mathieu,et al.  Identification and immune regulation of 25‐hydroxyvitamin D‐1‐α‐hydroxylase in murine macrophages , 2000, Clinical and experimental immunology.

[71]  H. Spiegelberg,et al.  Immunosuppressive actions of 1,25-dihydroxyvitamin D3: preferential inhibition of Th1 functions. , 1995, The Journal of nutrition.

[72]  D. Bikle,et al.  1,25-Dihydroxyvitamin D3 potentiates the keratinocyte response to calcium. , 1994, The Journal of biological chemistry.

[73]  B. Spiegelman,et al.  Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. , 1993, Science.

[74]  E. Lothman,et al.  Dormancy of inhibitory interneurons in a model of temporal lobe epilepsy. , 1993, Science.

[75]  M. Fanger,et al.  Inhibition of T lymphocyte mitogenesis by 1,25-dihydroxyvitamin D3 (calcitriol). , 1984, The Journal of clinical investigation.

[76]  I. Macintyre Vitamin D metabolism. , 1973, The New England journal of medicine.

[77]  H. DeLuca,et al.  "Activation" of vitamin D by the liver. , 1969, The Journal of clinical investigation.